Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium versus quetiapine add-on therapy in treatment-resistant depression
ISRCTN16387615Phase 4Completed
- Sponsor
- King's College London
- Start
- Nov 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial in major depressive disorder (MDD) and treatment-resistant depression (TRD) comparing Lithium add-on with Quetiapine add-on (2 arms). Primary endpoints: Longitudinal depressive symptom severity and Time to all-cause discontinuation. Started Nov 2016; status: completed.
02
Drugs
lithiumquetiapine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ISRCTN16387615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16387615.